Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655599 · ClinicalTrials.gov registry record · Phase 1
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1 study, sponsored by Arena Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04655599 is a Phase 1 study that was terminated before completion, run by Arena Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT04655599, a Phase 1 study, was terminated before completion, sponsored by Arena Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
Interventions
- DRUG Placebo
- DRUG Olorinab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2021-04-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04655599
The ClinicalTrials.gov registry entry for NCT04655599 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04655599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04655599 about?
NCT04655599 is a clinical study titled "Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome". A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
What is the current status of trial NCT04655599?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2021-01-29. Estimated completion is 2021-04-13.
What interventions are being tested in trial NCT04655599?
The interventions under investigation include: Placebo (DRUG), Olorinab (DRUG).
Who is sponsoring clinical trial NCT04655599?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.